Global Urinary Tract Infections Therapeutics Market size was valued at US$ 2.80 Bn in 2022 and the total revenue is expected to grow at 4.1% through 2023 to 2029, reaching nearly US$ 3.72 Bn.Urinary Tract Infections Therapeutics Market Overview:
In most people, a urinary tract infection (UTI) is one of the most common health problems. As women experience health issues such as menopause, pregnancy, and some birth control side effects, UTI is more common in women than in males. On a global scale, however, the urinary tract infection treatment market is hampered by people's apprehension about consulting doctors and healthcare providers for an accurate diagnosis. In hospitalized patients suffering from complex urinary tract infections, ongoing research and development activities in the urinary tract infection treatment market highlight the predictive features of multidrug-resistant gram-negative bacteria (cUTI).To know about the Research Methodology :- Request Free Sample Report
Market Dynamics:
As per a study published in Advances in Urology in 2021, kidney stone disease is a growing urological health problem that affects roughly 15% of the world's population. It affects people of all ages, but it affects males more than women between the ages of 20 and 49. Furthermore, roughly 7% of women and 13% of men will acquire a kidney stone during their lives. As a result, as the pervasiveness of diabetes and kidney stones upsurges, the number of cases of urinary tract infection (UTI) rises, increasing medicine demand and driving the global urinary tract infection therapeutics market. In addition, the market for urinary tract infection therapies is predicted to rise due to the introduction of more effective combination medications and the growing geriatric population. According to the Center for Education and Research on Therapeutics, about 2 million adverse drug reactions (ADRs) are recorded each year, resulting in over 100,000 deaths and as per the FDA, over 350,000 adverse drug reactions (ADRs) occur in nursing homes alone in the United States each year. With an increase in the number of incidences of adverse drug reactions (ADRs) being recorded globally, there is a greater public awareness of the importance of medication adoption, which is a major restraint for the urinary tract infection treatments market. In addition, in impoverished nations, there is a lack of awareness regarding the prevalence of UTIs, which is limiting market growth in the forecast timeframe.Urinary Tract Infections Therapeutics Market Segment Analysis:
The Quinolones segment is dominating the Drug segment of the Global Urinary Tract Infections Therapeutics Market: Quinolones segment is estimated to boost the global urinary tract infection therapeutics market expansion in the projected time frame. The introduction of numerous mutant bacterial strains around the world has increased the prevalence of infectious diseases. Other factors include the rising prevalence of multi-drug-resistant bacteria, which raises healthcare concerns while also providing sufficient growth prospects for pharmaceutical companies. Quinolones may be able to partially replace other medication therapy due to their significant advantages over other antibacterial medicines. Good oral absorption, quicker tissue penetration, lesser side effects, easy once- or twice-daily dose, and broad-spectrum effectiveness against various pathogenic bacterial strains are just a few of the advantages. Some of the most used quinolones are norfloxacine, ciprofloxacine, enoxacine, moxifloxacin, gatifloxacine, levofloxacine, and trovafloxacine. The Complicated UTIs segment is considered to supplement the growth of the Global Urinary Tract Infections Therapeutics Market. The complicated UTIs segment is projected to dominate the market growth of the global urinary tract infection therapeutics market due to the overall rise in drug-resistant bacteria and overuse of antibiotics. Quinolones are prescribed by the great majority of doctors to treat complex UTI situations. Cephalosporin is the second-most-prescribed antibiotic for complex UTIs. Kidney stones are a prevalent illness, as per the American Academy of Family Physicians (AAFP), with an annual incidence of eight cases per 1,000 persons. However, around 13% of men and 7% of women may suffer from kidney stones during their lifetime, and the total incidence of urinary retention in the United States is 4.5 to 6.8 per 1,000 males per year. Overall, the prevalence of complicated UTI is expected to climb over the projected period, owing to rising bacterial resistance in UTI patients and a higher recurrence rate.Regional Insights:
North America is estimated to grow with the highest CAGR in the forecast timeframe. The factors affecting the growth of the market are an increase in innovations related to diagnostic methodologies used for UTI. During a regular checkup for a urinary tract infection, a woman was found to be infected with E. coli that was resistant to the last-resort drug, Colistin. The finding of Colistin-resistant bacteria was regarded as a significant problem. In addition, the CDC produced guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States in conjunction with other organizations. Major countries of North America are US, Canada, and Mexico. The objective of the report is to present a comprehensive analysis of the Global Urinary Tract Infections Therapeutics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Global Urinary Tract Infections Therapeutics Market dynamics, structure by analyzing the market segments and project the Global market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global market make the report investor’s guide.Urinary Tract Infections Therapeutics Market Scope: Inquire before buying
Urinary Tract Infections Therapeutics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 2.80 Bn. Forecast Period 2023 to 2029 CAGR: 4.1% Market Size in 2029: US $ 3.72 Bn. Segments Covered: by Drug Penicillin and Combinations Quinolones Cephalosporin Azoles and Amphotericin B Nitrofurans Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline) by Indications Complicated UTI Uncomplicated UTI Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.) Urinary Tract Infections Therapeutics Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Urinary Tract Infections Therapeutics Market, Key Players are:
1. Allergan 2. Bayer AG 3. Pfizer, Inc. 4. GlaxoSmithKline plc 5. Bristol-Myers Squibb Company 6. Janssen Global Services, LLC 7. Lupin Ltd. 8. Merck & Co., Inc 9. (Merck Sharp & Dohme Corp) 10.Dr. Reddy’s Laboratories Ltd. 11.Almirall, S.A 12.Cipla 13.Shionogi and Co., Ltd 14.Abbott laboratories 15.AbbVie Inc. 16.Boehringer Ingelheim International GmbH 17.Novartis AGFAQs:
1. What is the global Urinary Tract Infections Therapeutics market value in 2022? Ans: Global market value in 2022 was estimated as USD 2.80 Billion USD. 2. What is the global Urinary Tract Infections Therapeutics market growth? Ans: The global market is anticipated to grow with a CAGR of 4.1% in the forecast period and is likely to reach USD 3.72 Billion by the end of 2029. 3. Which Drug segment is expected to dominate the global Urinary Tract Infections Therapeutics market during the forecast period? Ans: The Complicated UTI segment is projected to dominate the market growth of the global urinary tract infection therapeutics market due to the overall rise in drug-resistant bacteria and overuse of antibiotics. 4. Who are the key players in the Urinary Tract Infections Therapeutics market? Ans: Some key players operating in the market include Allergan, Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Lupin Ltd., Merck & Co., Inc (Merck Sharp & Dohme Corp), Dr. Reddy’s Laboratories Ltd., Almirall, S.A., Cipla, Shionogi and Co., Ltd, Abbott Laboratories, AbbVie Inc., Boehringer Ingelheim International GmbH. 5. What is the key driving factor for the growth of the global Urinary Tract Infections Therapeutics market? Ans: Key factors that are driving the market growth include the pervasiveness of diabetes and kidney stones upsurges, the number of cases of urinary tract infection (UTI) rises, increasing medicine demand, and driving the global urinary tract infection therapeutics market.
1.Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Urinary Tract Infections Therapeutics Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Urinary Tract Infections Therapeutics Market 3.4. Geographical Snapshot of the Urinary Tract Infections Therapeutics Market, By Manufacturer share 4. Global Urinary Tract Infections Therapeutics Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Urinary Tract Infections Therapeutics Market 5. Supply Side and Demand Side Indicators 6. Global Urinary Tract Infections Therapeutics Market Analysis and Forecast, 2022-2029 6.1. Global Urinary Tract Infections Therapeutics Market Size & Y-o-Y Growth Analysis. 7. Global Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 7.1.1. Penicillin and Combinations 7.1.2. Quinolones 7.1.3. Cephalosporin 7.1.4. Azoles and Amphotericin B 7.1.5. Nitrofurans 7.1.6. Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, 7.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 7.2.1. Complicated UTI 7.2.2. Uncomplicated UTI 7.2.3. Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.) 8. Global Urinary Tract Infections Therapeutics Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 9.1.1. Penicillin and Combinations 9.1.2. Quinolones 9.1.3. Cephalosporin 9.1.4. Azoles and Amphotericin B 9.1.5. Nitrofurans 9.1.6. Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, 9.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 9.2.1. Complicated UTI 9.2.2. Uncomplicated UTI 9.2.3. Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.) 10. North America Urinary Tract Infections Therapeutics Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 12. Canada Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 13. Mexico Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 14. Europe Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 15. Europe Urinary Tract Infections Therapeutics Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 17. France Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 18. Germany Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 19. Italy Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 20. Spain Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 21. Sweden Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 22. CIS Countries Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 23. Rest of Europe Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 24. Asia Pacific Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 25. Asia Pacific Urinary Tract Infections Therapeutics Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 27. India Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 28. Japan Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 29. South Korea Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 30. Australia Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 31. ASEAN Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 32. Rest of Asia Pacific Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 33. Middle East Africa Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 34. Middle East Africa Urinary Tract Infections Therapeutics Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 36. GCC Countries Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 38. Nigeria Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 39. Rest of ME&A Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 40. South America Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 41. South America Urinary Tract Infections Therapeutics Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 43. Argentina Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 44. Rest of South America Urinary Tract Infections Therapeutics Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Drug, 2022-2029 44.2. Market Size (Value) Estimates & Forecast By Indications, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Urinary Tract Infections Therapeutics Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Novartis AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. Allergan 45.3.3. Bayer AG 45.3.4. Pfizer, Inc. 45.3.5. GlaxoSmithKline plc 45.3.6. Bristol-Myers Squibb Company 45.3.7. Janssen Global Services, LLC 45.3.8. Lupin Ltd. 45.3.9. Merck & Co., Inc 45.3.10. (Merck Sharp & Dohme Corp) 45.3.11. Dr. Reddy’s Laboratories Ltd. 45.3.12. Almirall, S.A 45.3.13. Cipla 45.3.14. Shionogi and Co., Ltd 45.3.15. Abbott laboratories 45.3.16. AbbVie Inc. 45.3.17. Boehringer Ingelheim International GmbH 46. Primary Key Insights